Skip to main content
Clinical Trials/NCT02402569
NCT02402569
Terminated
Early Phase 1

Implantation Feasibility Study of a Multi-electrodes Set for Deep Brain Stimulation in Parkinson Disease (Smart in Vivo 2)

University Hospital, Grenoble1 site in 1 country2 target enrollmentDecember 2014

Overview

Phase
Early Phase 1
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
University Hospital, Grenoble
Enrollment
2
Locations
1
Primary Endpoint
Safety, as measured by Number of Participants with Adverse Events
Status
Terminated
Last Updated
7 years ago

Overview

Brief Summary

This study aims to demonstrate innocuity and feasibility of deep brain stimulation with a multi-electrodes set.

Detailed Description

Bilateral stimulation in subthalamic nucleus with the multi-electrodes set will be compared with single electrode.

Registry
clinicaltrials.gov
Start Date
December 2014
End Date
December 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
University Hospital, Grenoble
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • more or equal than 18 years old and less than 70 years
  • patient affiliated to social security or similarly regime
  • informed consent form signed
  • parkinson disease (UPDRS III20 score up than 30/108 except for severe tremors)
  • motor and non motor dysfunctions
  • pre-operative cerebral MRI without lesion
  • without chirurgical contraindications
  • without psychiatric disease

Exclusion Criteria

  • Pregnant women and lactating mothers
  • Ward of court or under guardianship
  • Adult unable to express their consent
  • Person deprived of freedom by judicial or administrative decision
  • Person hospitalized without their consent
  • Person under legal protection
  • Person with carcinological antecedent during precedent 5 years
  • Chirurgical or MRI contraindications

Outcomes

Primary Outcomes

Safety, as measured by Number of Participants with Adverse Events

Time Frame: 3 months

Number of Participants with Adverse Events

Secondary Outcomes

  • Neurologic evaluation(3 months)

Study Sites (1)

Loading locations...

Similar Trials